GHK-Cu vs TB-500

GHK-Cu

The copper-binding tripeptide your skin loses with age. Strongest evidence is topical for skin and wound healing; injectable use is mostly anecdotal.

Best for

Best when the goal is skin quality, hair, and slow connective-tissue improvement. Cosmetic territory.

TB-500

A synthetic fragment of Thymosin Beta-4 used for systemic tissue repair. Sister peptide to BPC-157, but where BPC works locally, TB-500 spreads.

Best for

Best when the goal is actual injury recovery — muscle, tendon, ligament regeneration. Functional territory.

GHK-Cu

Topical cosmetic and wound-healing data is the strongest part of the literature — small but real RCTs from the 1990s and 2000s for skin firmness, wrinkle depth, and diabetic ulcer healing. Loren Pickart's group has been the principal driver of this research for decades. Injectable systemic use has minimal human trial data and the gene-modulation claims that circulate online come from in vitro work, not clinical trials.

TB-500

Animal data is substantial — TB-500's parent protein Thymosin Beta-4 has been studied in wound healing, cardiac repair, and neural regeneration for decades. The 2012 Goldstein and Hannappel review covers the preclinical body of work. Human data is essentially absent: a small Phase 2 trial in dry-eye disease (RegeneRx) showed signal but didn't lead to approval, and the racehorse-doping literature is informative but not human-clinical. Use anecdotal-plus-animal as your evidence floor, not as a substitute for the missing human RCTs.